Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (BNTX)
NASDAQ:BNTX
BioNTech SE (BNTX) Stock Price & Analysis
4,247 Followers
BNTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$78.02 - $125.83
Previous Close$85.46
Volume433.89K
Average Volume (3M)731.58K
Market Cap
$20.32B
Enterprise Value$3.99B
Total Cash (Recent Filing)€16.55B
Total Debt (Recent Filing)€219.10M
Price to Earnings (P/E)166.2
Beta0.22
Next Earnings
Aug 05, 2024EPS Estimate
-$2.17Last Dividend Ex-Date
Jun 02, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)0.51
Shares Outstanding237,725,735
10 Day Avg. Volume689,301
30 Day Avg. Volume731,583
Standard Deviation0.23
R-Squared0.00383
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)1.05
Price to Sales (P/S)5.27
Price to Cash Flow (P/CF)5.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$112.45Price Target Upside31.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
BioNTech SE News
PremiumCompany Announcements
BioNTech’s Omicron Vaccine Set for EU Rollout
PremiumCompany Announcements
BioNTech’s New Cancer Drug Fast-Tracked by FDA
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsZero BNT122 patients showed disease progression with median 640-day follow-up, impressive given both ctDNA positive (poor prognosis) and negative (good prognosis) patients were included.
Oncology PipelineThe company has several additional ongoing projects in oncology.
Regulatory ApprovalsBNT324 receives Fast Track designation.
Bears Say
Commercial RisksComirnaty (COVID-19 vaccine) market share erosion is increasingly likely due, in part, to Sanofi enabling the commercialization of peptide-based COVID and COVID/flu vaccines under the Sanofi/Novavax partnership.
Financial PerformanceBioNTech recorded a net loss per diluted share of €1.31 per share—meaningfully worse than the previous forecast for net earnings of €1.18 per share; this was primarily due to significantly lower-than-expected COMIRNATY revenues.
Regulatory IssuesBNT326, the company’s HER3 antibody drug conjugate (ADC), was placed under a partial clinical hold by the FDA resulting in an enrollment pause of US patients.
---
Ownership Overview
0.68% Insiders
4.71% Mutual Funds
1.32% Other Institutional Investors
93.29% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BNTX FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest stock price was $78.02 and its highest was $125.83 in the past 12 months.
What is BioNTech SE’s market cap?
Currently, no data Available
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is Aug 05, 2024 which is in 14 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on May 06, 2024. The company reported -$1.427 earnings per share for the quarter, missing the consensus estimate of -$1.354 by -$0.073.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE pays a Notavailable dividend of $1.53 which represents an annual dividend yield of N/A. See more information on BioNTech SE dividends here
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is -$2.17.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 237,725,740 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of -$1.427 in its last earnings report, missing expectations of -$1.354. Following the earnings report the stock price went up 0.679%.
Which hedge fund is a major shareholder of BioNTech SE?
Among the largest hedge funds holding BioNTech SE’s share is PRIMECAP Management Co. It holds BioNTech SE’s shares valued at 444M.
---
BioNTech SE Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$112.45 (31.58% Upside)
$112.45 (31.58% Upside)
Blogger Sentiment
Bullish
BNTX Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 436.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.68%
12-Months-Change
Fundamentals
Return on Equity
0.54%
Trailing 12-Months
Asset Growth
0.21%
Trailing 12-Months
Company Description
BioNTech SE
BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.
---
BNTX Company Deck
---
BNTX Earnings Call
Q1 2024
0:00 / 0:00
---
BNTX Stock 12 Month Forecast
Average Price Target
$112.45
▲(31.58% Upside)
Technical Analysis
Best Analysts Covering BNTX
1 Year
1 Year Success Rate
3/14 ratings generated profit
1 Year Average Return
+15.67%
assigned a buy rating last month
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 21.43% of your transactions generating a profit, with an average return of +15.67% per trade.
---